MedTrace Logo

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

NCT03698071 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-05-28

No results posted yet for this study

Summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Conditions

  • ANCA Associated Vasculitis

Interventions

BIOLOGICAL

blood sample

30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

BIOLOGICAL

urine sample

6 ml

Sponsors & Collaborators

  • National Research Agency, France

    collaborator OTHER

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Patrick BLANCO, Prof · University Hospital, Bordeaux

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2024-09-18
Completion
2024-09-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698071 on ClinicalTrials.gov